Literature DB >> 29089178

Effect of anticoagulants on 162 circulating immune related proteins in healthy subjects.

Rianne C Scholman1, Barbara Giovannone2, Sanne Hiddingh3, Jenny M Meerding1, Beatriz Malvar Fernandez3, Mariska E A van Dijk4, Mariëlle J Tempelman4, Berent J Prakken1, Wilco de Jager5.   

Abstract

Diagnosis of complex disease and response to treatment is often associated with multiple indicators, both clinical and laboratorial. With the use of biomarkers, various mechanisms have been unraveled which can lead to better and faster diagnosis, predicting and monitoring of response to treatment and new drug development. With the introduction of multiplex technology for immunoassays and the growing awareness of the role of immune-monitoring during new therapeutic interventions it is now possible to test large numbers of soluble mediators in small sample volumes. However, standardization of sample collection and laboratory assessments remains suboptimal. We developed a multiplex immunoassay for detection of 162 immune related proteins in human serum and plasma. The assay was split in panels depending on natural occurring concentrations with a maximum of 60 proteins. The aim of this study was to evaluate precision, accuracy, reproducibility and stability of proteins when repeated freeze-thaw cycles are performed of this in-house developed panel, as well as assessing the protein signature in plasma and serum using various anticoagulants. Intra-assay variance of each mediator was <10%. Inter-assay variance ranged between 1.6 and 37% with an average of 12.2%. Recoveries were similar for all mediators (mean 99.8 ± 2.6%) with a range between 89-107%. Next we measured all mediators in serum, EDTA plasma and sodium heparin plasma of 43 healthy control donors. Of these markers only 19 showed similar expression profiles in the 3 different matrixes. Only 5 mediators were effected by multiple freeze-thawing cycles. Principal component analysis revealed different coagulants cluster separately and that sodium heparin shows the most consistent profile.
Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Anticoagulants; Cytokine; Luminex; Plasma; Serum; Validation

Mesh:

Substances:

Year:  2017        PMID: 29089178     DOI: 10.1016/j.cyto.2017.10.021

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  9 in total

Review 1.  Considerations for Soluble Protein Biomarker Blood Sample Matrix Selection.

Authors:  Joel A Mathews; Yan G Ni; Connie Wang; Jon E Peterson; Chad Ray; Xuemei Zhao; Daoyu Duan; Sara Hamon; John Allinson; Martha Hokom; Greta Wegner
Journal:  AAPS J       Date:  2020-01-29       Impact factor: 4.009

2.  Human Platelet Lysate as Alternative of Fetal Bovine Serum for Enhanced Human In Vitro Bone Resorption and Remodeling.

Authors:  Bregje W M de Wildt; Keita Ito; Sandra Hofmann
Journal:  Front Immunol       Date:  2022-06-20       Impact factor: 8.786

3.  Inflammatory response and optimalisation of perioperative fluid administration during hyperthermic intraoperative intraperitoneal chemotherapy surgery.

Authors:  Piet de Witte; Christien A de Witt; Johan L van de Minkelis; Djamila Boerma; H Frank Solinger; C Erik Hack; Peter Bruins
Journal:  J Gastrointest Oncol       Date:  2019-04

4.  Effect of cytomegalovirus reactivation on the time course of systemic host response biomarkers in previously immunocompetent critically ill patients with sepsis: a matched cohort study.

Authors:  Kirsten van de Groep; Stefan Nierkens; Olaf L Cremer; Linda M Peelen; Peter M C Klein Klouwenberg; Marcus J Schultz; C Erik Hack; Tom van der Poll; Marc J M Bonten; David S Y Ong
Journal:  Crit Care       Date:  2018-12-18       Impact factor: 9.097

5.  Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study.

Authors:  Nienke M Ter Haar; E H Pieter van Dijkhuizen; Joost F Swart; Annet van Royen-Kerkhof; Ayman El Idrissi; Arjen P Leek; Wilco de Jager; Mark C H de Groot; Saskia Haitjema; Dirk Holzinger; Dirk Foell; Jorg van Loosdregt; Nico M Wulffraat; Sytze de Roock; Sebastiaan J Vastert
Journal:  Arthritis Rheumatol       Date:  2019-05-25       Impact factor: 10.995

6.  Galectin-9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation.

Authors:  Judith Wienke; Felicitas Bellutti Enders; Johan Lim; Jorre S Mertens; Luuk L van den Hoogen; Camiel A Wijngaarde; Joo Guan Yeo; Alain Meyer; Henny G Otten; Ruth D E Fritsch-Stork; Sylvia S M Kamphuis; Esther P A H Hoppenreijs; Wineke Armbrust; J Merlijn van den Berg; Petra C E Hissink Muller; Janneke Tekstra; Jessica E Hoogendijk; Claire T Deakin; Wilco de Jager; Joël A G van Roon; W Ludo van der Pol; Kiran Nistala; Clarissa Pilkington; Marianne de Visser; Thaschawee Arkachaisri; Timothy R D J Radstake; Anneke J van der Kooi; Stefan Nierkens; Lucy R Wedderburn; Annet van Royen-Kerkhof; Femke van Wijk
Journal:  Arthritis Rheumatol       Date:  2019-03-12       Impact factor: 10.995

7.  Neonatal Antibiotic Treatment Is Associated With an Altered Circulating Immune Marker Profile at 1 Year of Age.

Authors:  Berthe C Oosterloo; Belinda Van't Land; Wilco de Jager; Nicole B Rutten; Margot Klöpping; Johan Garssen; Arine M Vlieger; Ruurd M van Elburg
Journal:  Front Immunol       Date:  2020-01-10       Impact factor: 7.561

8.  Inflammatory marker trajectories associated with frailty and ageing in a 20-year longitudinal study.

Authors:  Leonard Daniël Samson; Anne-Marie Buisman; José A Ferreira; H Susan J Picavet; W M Monique Verschuren; Annemieke Mh Boots; Peter Engelfriet
Journal:  Clin Transl Immunology       Date:  2022-02-09

9.  Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis.

Authors:  Lies Hulshof; Saskia A Overbeek; Anne L Wyllie; Mei Ling J N Chu; Debby Bogaert; Wilco de Jager; Leon M J Knippels; Elisabeth A M Sanders; Wim M C van Aalderen; Johan Garssen; Belinda Van't Land; Aline B Sprikkelman
Journal:  Front Immunol       Date:  2018-03-29       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.